AstraZeneca bails on roxadustat’s future in the US, but keeps China pact with FibroGen
AstraZeneca is handing back US and certain other regional rights for roxadustat to FibroGen, ending a two-and-a-half-year limbo that followed an FDA rejection of the anemia drug.
The two companies will keep their deals in China and South Korea, where roxadustat is already approved, FibroGen added in a Monday release. In 2023, roxadustat net sales in China totaled $284.1 million, the biotech reported in its concurrent full-year earnings report, adding that it’s expecting an approval decision in chemotherapy-induced anemia in the country later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
